As part Medical marijuana of the Transaction, the Company changed its name from BFK Capital Corp. to The Hydropothecary Corporation and the directors and management of THC became the directors and management of the Company. As a result of the Transaction, THC is now a wholly-owned subsidiary of the Company, and the Company will continue the business of THC which, through its wholly-owned subsidiary, 167151 Canada Inc., is licensed under the Access to Cannabis for Medical Purposes Regulations to cultivate and sell marijuana seeds and plants and dried marijuana product and to produce marijuana oils, marijuana resins and fresh marijuana products from its facilities located in Gatineau, Quebec. Prior to the Transaction, BFK was a Capital Pool Company (as defined under the policies of the TSX Venture Exchange (the Exchange)), and had not commenced commercial operations and had no assets other than cash. In connection with the Transaction, immediately prior to closing, BFK consolidated its common shares on the basis of one (1) post-consolidation common share for each one and a half (1.5) pre-consolidation common shares. The Transaction constituted BFKs Qualifying Transaction, as such term is defined in Policy 2.4 of the Exchange. Final acceptance of the Transaction will occur upon the issuance of a Final Exchange Bulletin by the Exchange. Upon issuance of the Final Exchange Bulletin, the Company will cease to be a Capital Pool Company and will recommence trading on the Exchange as a Tier 1 life sciences issuer. Subject to this final acceptance, trading in the common shares of the Company is expected to begin on the Exchange on or about March 21, 2017 under the symbol THCX. The closing of this transaction is a significant milestone in the continued growth of Hydropothecary. Sebastien St-Louis, Chief Executive Officer of the Company In connection with the Transaction, THC completed a brokered private placement through Canaccord Genuity Corp.